NRSN NeuroSense Therapeutics Ltd: Net earnings per one share for the last twelve months
NeuroSense Therapeutics (NRSN) is accelerating the development of its breakthrough PrimeC combination therapy to combat ALS. The monopoly status of these future drugs will grant the company full pricing power. The biopharmaceutical ecosystem is creating a closed treatment loop with high switching costs, as confirmed by the trailing twelve-month (TTM) EPS growth chart on GURU.Markets, where the current metric is 31.40.
NRSN (NeuroSense Therapeutics Ltd): analytical breakdowns and indicator data
- current price and projected stock value:
- company stock capitalization data:
- company book value details:
- debt and liquidity data:
Debt to Equity Ratio NeuroSense Therapeutics|NRSN - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient neurosense-tx.com|NRSN - Company Aggregate Debts|Debts to Book Value NeuroSense Therapeutics|NRSN - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings NeuroSense Therapeutics|Intermediate Liquidity Ratio neurosense-tx.com
- business earnings and investment ratios data:
NRSN - Net Profit|Expected Net Income NeuroSense Therapeutics|NRSN - P/E Multiple|Projected Price to Earnings Ratio NeuroSense Therapeutics Ltd.|NRSN - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation NeuroSense Therapeutics, Ltd.|NRSN - Operating profit EBITDA|Net earnings per share (EPS TTM) NeuroSense Therapeutics|NRSN - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months neurosense-tx.com|NRSN - Earnings growth in current year|Expected net earnings per share growth next year NeuroSense Therapeutics
- sales and revenue indicators:
Fundamental company valuation:NRSN, NeuroSense Therapeutics
Year-over-year (YoY) EPS growth (TTM) measures the percentage change in net income per share over the trailing twelve months, reflecting the dynamics of real shareholder income relative to the previous year. For NeuroSense Therapeutics (NRSN), the current EPS YoY TTM growth trend serves as an indicator of financial efficiency amid the clinical trials of the PrimeC drug and the company's acquisition prospects.
Direct competitors
Net earnings per share for the trailing year Biogen (BIIB)|neurocrine.com (NBIX) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months Regencell|AXSM (Axsome) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) ACADIA Pharmaceuticals Inc.|Earnings per share for the last twelve months Xenon Pharmaceuticals (XENE)|VKTX (Viking Pharma) - Earnings per share for the trailing year|Earnings per share for the last twelve months Supernus Corp SUPN|Earnings per share for the last four quarters CPRX (Catalyst Pharmaceuticals)|Denali Therapeutics - Net earnings per share (EPS TTM)|HRMY: Earnings per share for the last twelve months|Biohaven (BHVN) - Earnings per share for the last twelve months|Amylyx Pharmaceuticals Inc (AMLX) - Net earnings per share (EPS TTM)|TRVI (Trevi Therapeutics Inc) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Praxis Medicines (PRAX)|Net earnings per share for the last 12 months AVXL (Anavex Life Sciences)|Net earnings per share for the last 12 months CeriBell CBLL|Earnings per share for the last twelve months Prothena Biosciences PRTA|Net earnings per share (EPS TTM) Alector, Inc. ALEC|ANNX - Earnings per share for the last twelve months|OMER - Net earnings per share (EPS TTM)|Neurogene (NGNE) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months AC Immune SA (ACIU)|Net earnings per share for the last 12 months VYGR|Net earnings per share (EPS TTM) Neumora Therapeutics Inc|Earnings per share for the last twelve months scilexholding.com (SCLX)|Net earnings per share for the last four quarters Tevogen Bio Inc.|Earnings per share for the last twelve months Alpha Cognition Inc. ACOG|Net earnings per share (EPS TTM) Cognition Therapeutics CGTX|IKT: Net earnings per share for the last 12 months|SAVA (Cassava Sciences) - Earnings per share for the last 12 months|Assertio Holdings, Inc. (ASRT) - Earnings per share for the last twelve months|Earnings per share for the last 12 months COYA|Earnings per share for the last twelve months Vistagen|Net earnings per share for the last 12 months Ovid Therapeutics (OVID)|Earnings per share for the last twelve months Acumen Pharmaceuticals Inc. (ABOS)|CRVO - Net earnings per one share for the last twelve months|Alterity Therapeutics Limited - Net earnings per share for the last 12 months|CLNN: Earnings per share for the last 12 months|pepgen.com - Net earnings per share (EPS TTM)|JUNS (Jupiter Neurosciences) - Earnings per share for the last 12 months|Relmada (RLMD) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Annovis Bio (ANVS)|GRCE (gracetx.com) - Net earnings per share (EPS TTM)|Firefly Neuroscience Inc (AIFF) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months KLTO (Klotho Neurosciences Inc)|Reviva Pharmaceuticals - Earnings per share for the last 12 months|MetaVia Inc - Net earnings per share for the last 12 months|NRXS: Earnings per share for the last 12 months|HSDT - Earnings per share for the last twelve months|Net earnings per share for the last four quarters passagebio.com PASG|NEUP (Neuphoria Therapeutics) - Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months minervaneurosciences.com (NERV)|ATHA (Athira Pharma Inc) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Addex Therapeutics, Ltd. ADXN|Net earnings per share (EPS TTM) ALZN|Net earnings per share for the last 12 months Cyclerion CYCN|Earnings per share for the last twelve months Protagenic Therapeutics Inc. PTIX|Net earnings per share for the last four quarters Pasithea (KTTA)|Cortigent Inc - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Avenue Therapeutics, Inc|BCLI (Brainstorm Cell Therapeutics, Inc.) - Net earnings per share for the last 12 months|Cara Therapeutics, Inc. (CARA) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Chromocell Therapeutics Corp|Net earnings per one share for the last twelve months eliemtx.com ELYM|Earnings per share for the last twelve months Intra-Cellular Therapies Inc. (ITCI)|Longboard Pharmaceuticals, Inc. - Earnings per share for the last 12 months|Marinus Pharmaceuticals Inc - Net earnings per share for the last 12 months|NKGen (NKGN) - Net earnings per one share for the last twelve months|NRBO - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months sagerx.com|SNPX: Net earnings per share (EPS TTM)|Trevena Inc. (TRVN) - Net earnings per share (EPS TTM)|VIGL (Vigil Neuroscience, Inc.) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months WENA (Anew Medical, Inc.)|Net earnings per share (EPS TTM) CERE
